Interestingly, it was recently shown that increased levels of TRIB3 were associated with elevated EGFR stability and signaling activity in lung cancer, suggesting that the disruption of the TRIB3-EGFR interaction could be a novel therapeutic target [97]. The gene discussed is TRIB3; the disease is lung carcinoma.